Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Overweight: full-pipeline trial registry
50 of 198 indexed Overweight trials are currently recruiting.
Corpus placement: #52 of 28,707 conditions by registered trial count.
198 US clinical trials · 50 currently recruiting · #52 of 28,707 conditions by registered trial count
Overweight: 198 US clinical trials tracked, 50 recruiting.
Overweight is the subject of 198 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 37 are in Phase 3-4 (later-stage) and 46 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 37 of these trials.
Enrollment posture brief
Registry condition overweight
OPEN 50 | RECR 25% | LATE 37 | EARLY 46 | RANK #52 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)
Overweight lists 50 open slots (25% of 198 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Overweight on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Overweight is recruiting below its size-band peers.
50 of 198 indexed trials (25.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Overweight research.
Eli Lilly and Company accounts for 37 of 198 trials (18.7%). 94 distinct sponsors appear on at least one study for this condition label.
-
Typical Overweight enrolment sits around 120 participants.
Median target enrolment is 120 among the 198 trials that report a genuine target (sentinel values excluded). 89 of those (44.9%) plan for fewer than 100 participants.
-
Overweight research is mostly interventional.
182 interventional and 16 observational studies make up this index (91.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
198 total, page 3 of 4
Delivering Geospatial Intelligence to Health Care Providers
Indiana University
NCT01567228
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
Novo Nordisk A/S
NCT05035095
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Eli Lilly and Company
NCT04657016
Mothers in Motion Program to Prevent Weight Gain in WIC Mothers (MIM)
Ohio State University
NCT01839708
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
Orexigen Therapeutics
NCT00474630
A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
Novartis Pharmaceuticals
NCT03100058
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
Novartis Pharmaceuticals
NCT00219141
Targeting Inflammation Using Salsalate in CardioVascular Disease
Joslin Diabetes Center
NCT00624923
Growing Resilience in Wind River Indian Reservation
University of Wyoming
NCT02672748
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Eli Lilly and Company
NCT04881760
Multicenter Worksite Nutrition Study
Physicians Committee for Responsible Medicine
NCT01224548
A Randomized Trial of Recommendations for Exercise to Prevent Weight Regain
University of Kansas
NCT01664715
Toddler Overweight Prevention Study Among Low-Income Families
University of Maryland, Baltimore
NCT02615158
Weight Watchers Online
The Miriam Hospital
NCT01888172
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
AstraZeneca
NCT00402077
Barriers to Effective Weight Loss in Overweight Adolescents
Virginia Commonwealth University
NCT00562263
Dissemination of the Look Ahead Weight Management Treatment in the Military
University of Tennessee
NCT02063178
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women
Mondelēz International
NCT00932516
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
Orexigen Therapeutics
NCT01764386
Families Improving Together (FIT) for Weight Loss
University of South Carolina
NCT01796067
Weight Loss Maintenance in Primary Care
Drexel University
NCT00455780
Ethnic Dance and Screen Time Reduction to Prevent Weight Gain in Latina Girls
Stanford University
NCT00476775
UCSD Take Charge Study
University of California, San Diego
NCT01345500
Examining the Feasibility of Collaborative Care Treatment for Overweight Adolescents
Kaiser Permanente
NCT00462267
mFit: The Mobile Fitness Project
University of California, Los Angeles
NCT01650337
Eating Peanuts for Health
Purdue University
NCT01886326
Strong Hearts: Rural CVD Prevention
Cornell University
NCT02499731
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
Stanford University
NCT05249465
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
Scripps Whittier Diabetes Institute
NCT03552107
Getting in Balance: A Workplace Diabetes Prevention Intervention Trial
Kaiser Permanente
NCT02589873
Post-delivery Maternal-offspring Obesity and Metabolic Risk After a Prepregnancy Weight-loss Intervention
Kaiser Permanente
NCT06067126
Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women
University of Vermont
NCT02233673
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
NCT06824051
Self-Efficacy in Weight Loss Treatment
Lora Burke
NCT00896194
Examining the Longitudinal Relationship Between Sleep and Weight Gain in College Students
Oakland University
NCT04100967
A Study of Tirzepatide in Overweight and Very Overweight Participants
Eli Lilly and Company
NCT04311411
Worksite Nutrition Study
Physicians Committee for Responsible Medicine
NCT00481897
Motivating Value of Vegetables Study
USDA Grand Forks Human Nutrition Research Center
NCT02585102
Medications With or Without WeightWatchers
Michelle Cardel, PhD, MS, RD
NCT06470659
Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01862796
A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity
Novo Nordisk A/S
NCT07101783
PATH to Health: An Exploration of Digital Behavioral Weight Loss Approaches
University of North Carolina, Chapel Hill
NCT05929469
A Study of LY3841136 in Overweight and Obese Participants
Eli Lilly and Company
NCT06345066
Weight Watchers Online 2015
The Miriam Hospital
NCT02417220
Exercise Genes: Genomic Association With Exercise Reinforcement
USDA Grand Forks Human Nutrition Research Center
NCT02416882
A School Nurse-Delivered Intervention for Overweight and At Risk Adolescents
University of Massachusetts, Worcester
NCT00682188
Educational Intervention on Weight Management in Chinese-American Children
University of California, San Francisco
NCT00522964
Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study)
Johns Hopkins University
NCT00990457
An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children
University of Wisconsin, Madison
NCT01552642
Physical Activity Referrals to the Community
University of California, Berkeley
NCT02044744
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 25 |
| Phase 3 | 36 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Overweight records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Overweight trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Overweight page
198 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Overweight trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Overweight trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Overweight condition card totals 198 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.